GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study

被引：0
|
作者：
Thennati, Rajamannar [1 ]
Burade, Vinod [1 ]
Natarajan, Muthukumaran [1 ]
Shahi, Pradeep [1 ]
Nagaraja, Ravishankara [1 ]
Agrawal, Sudeep [1 ]
Jandrain, Bernard [2 ,3 ]
Duvauchelle, Thierry [4 ]
Pratley, Richard E. [5 ]
Thorens, Bernard [6 ]
Vilsboll, Tina [7 ]
Loomba, Rohit [8 ]
机构：
[1] Sun Pharmaceut Ind Ltd, High Impact Innovat Sustainable Hlth Solut HISH, Vadodara, India
[2] Acad Hosp Liege, Clin Pharmacol Unit, ATC Co, Liege, Belgium
[3] Acad Hosp Liege, Div Diabet Nutr & Metab Disorders, Liege, Belgium
[4] Phaster1, Paris, France
[5] AdventHealth Translat Res Inst, Orlando, FL USA
[6] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland
[7] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Clin Res, Copenhagen, Denmark
[8] Univ Calif San Diego, Sch Med, La Jolla, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-231
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 49 条
  • [41] The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
    Reis-Barbosa, Pedro H.
    Marcondes-de-Castro, Ilitch
    Marinho, Thatiany S.
    Aguila, Marcia Barbosa
    Mandarim-de-Lacerda, Carlos A.
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4613 - 4621
  • [42] Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study
    Stefanakis, Konstantinos
    Kokkinos, Alexander
    Argyrakopoulou, Georgia
    Konstantinidou, Sofia K.
    Simati, Stamatia
    Kouvari, Matina
    Kumar, Ajay
    Kalra, Bhanu
    Kumar, Melina
    Bontozoglou, Nikolaos
    Kyriakopoulou, Konstantina
    Mantzoros, Christos S.
    DIABETES OBESITY & METABOLISM, 2023, 25 (09): : 2561 - 2574
  • [43] Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study (vol 26, pg 5222, 2024)
    Huang, Y. N.
    Liao, W. L.
    Huang, J. Y.
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1630 - 1630
  • [44] The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials
    Liu, Yupeng
    Ruan, Binye
    Jiang, Huinan
    Le, Siyu
    Liu, Yi
    Ao, Xuemei
    Huang, Yufeng
    Shi, Xudong
    Xue, Ru
    Fu, Xiaoyi
    Wang, Shuran
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2023, 118 (03): : 614 - 626
  • [45] Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial
    Wu, Jingying
    Zhou, Renpeng
    Zhang, Qian
    Zhang, Qin
    Qin, Huiling
    Ye, Zi
    Xu, Yimei
    Feng, Sheng
    Shu, Chang
    Shen, Yu
    Fan, Yang
    Wang, Quanren
    Du, Yijun
    Hu, Wei
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 901 - 910
  • [46] Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study
    Kubota, Mitsunobu
    Yamamoto, Kazuki
    Yoshiyama, Sayo
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [47] ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1c study
    Ji, L.
    Zhou, H.
    Li, X.
    Xu, X.
    Wong, A.
    Zu, Y.
    Song, X.
    Zhang, Y.
    Lin, S.
    Zhang, X.
    Zhang, Y.
    DIABETOLOGIA, 2024, 67 : S81 - S81
  • [48] Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes
    Saxena, Aditi R.
    Frias, Juan P.
    Gorman, Donal N.
    Lopez, Rene N.
    Andrawis, Nabil
    Tsamandouras, Nikolaos
    Birnbaum, Morris J.
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2805 - 2814
  • [49] Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)
    Sprung, Victoria S.
    Kemp, Graham J.
    Wilding, John Ph
    Adams, Valerie
    Murphy, Kieran
    Burgess, Malcolm
    Emegbo, Stephen
    Thomas, Matthew
    Needham, Alexander J.
    Weimken, Andrew
    Schwab, Richard J.
    Manuel, Ari
    Craig, Sonya E.
    Cuthbertson, Daniel J.
    BMJ OPEN, 2020, 10 (07):
12345